Drug Trial Radar · NCT04812535
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
30
Actual
Start
Mar 31, 2021
Primary completion
Jun 4, 2024
Study completion Jun 4, 2024
Sponsor
- Lead sponsor
- InflaRx GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms
Conditions
- SCC - Squamous Cell Carcinoma of Skin
Interventions
VilobelimabDrug
Vilobelimab Monotherapy
Vilobelimab + pembrolizumab combination therapyDrug
Vilobelimab + pembrolizumab combination therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall Response Rate (Best ORR) - Arm A and Arm BTime frame: Up to 36 months
- Dose-limiting Toxicity (DLT) - Arm BTime frame: Cycle 1 Day 1 - Cycle 1 Day 36
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
UC San Diego Moores Cancer Center
La Jolla, California
Anschutz Cancer Pavilion
Aurora, Colorado
Sylvester Comprehensive Cancer Center
Miami, Florida
Orlando Health, Inc.
Orlando, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Inova Schar Cancer Institute
Fairfax, Virginia
University Hospital Antwerp (UZA)
Edegem, Belgium
St. Augustinus Hospital
Wilrijk, Belgium
University Hospital Center of Grenoble Alpes, Department of Dermatology
Grenoble, France
South Lyon Hospital Center
Lyon, France
CHU APHM la Timone / Aix Marseille University, Dermatology and Skin Cancer Department
Marseille, France
St. Louis Hospital
Paris, France
University Hospital Center of Poitiers, Department of Oncology
Poitiers, France
University Hospital Erlangen, Department of Dermatology
Erlangen, Germany
University Duisburg-Essen, University Hospital Essen, Department of Dermatology
Essen, Germany
Frankfurt University Clinic, Department of Dermatology, Venereology and Allergology
Frankfurt, Germany
University Hospital Hamburg-Eppendorf
Hamburg, Germany
University Hospital Leipzig, Department of Dermatology, Venereology and Allergology
Leipzig, Germany
University Hospital Regensburg, Clinic and Policlinic for Dermatology
Regensburg, Germany
University Hospital Tuebingen, Department of Dermatology
Tübingen, Germany
University Hospital Vall d'Hebron
Barcelona, Spain
ICO Hospitalet
Barcelona, Spain
MD Anderson International Cancer Center Spain
Madrid, Spain
Regional University Hospital of Malaga
Málaga, Spain
University Clinical Hospital of Salamanca
Salamanca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.